This study in healthy volunteers will provide a basis for evaluation of TRL345 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data, and provide serum samples for ex vivo studies of concentration-dependent antiviral activity to support the dose selection for as well as design and conduct of a clinical study in transplant patients.

Start Date14 Sep 2023

Sponsor / Collaborator

Trellis Bioscience, Inc.

[+1]

100 Clinical Results associated with HCMV gp

100 Translational Medicine associated with HCMV gp

0 Patents (Medical) associated with HCMV gp

Literatures (Medical) associated with HCMV gp

05 Mar 2021·Science AdvancesQ1 · CROSS-FIELD

Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion

Q1 · CROSS-FIELD

ArticleOA

Author: Yang, Xinzhen ; Che, Ye ; Han, Seungil ; Liu, Yuhang ; Dormitzer, Philip R. ; Heim, Kyle P. ; Chi, Xiaoyuan ; Qiu, Xiayang

Prefusion human cytomegalovirus glycoprotein B structure reveals the structural basis for membrane fusion.

01 Jul 2018·Journal of Pharmaceutical and Biomedical AnalysisQ3 · MEDICINE

A rapid magnetic particle-based enzyme immunoassay for human cytomegalovirus glycoprotein B quantification

Q3 · MEDICINE

Article

Author: Pires, F ; Castillo, Juan R ; Arcos-Martinez, M Julia ; Vidal, Juan C ; Dias-Cabral, A Cristina

Human cytomegalovirus (HCMV) is a herpes virus that can cause severe infections. Still, the available methods for its diagnostic have the main disadvantage of requiring long time to be performed. In this work, a simple magnetic particle-based enzyme immunoassay (mpEIA) for the quantification of glycoprotein B of Human cytomegalovirus (gB-HCMV) in urine samples is proposed. The immunosensor scheme is based on the analyte protein gB-HCMV sandwiched between a primary monoclonal antibody, (MBs-PrG-mAb1), and a secondary anti-gB-HCMV antibody labelled with Horseradish peroxidase (Ab2-HRP) to allow spectrophotometric detection. The mpEIA analytical performance was tested in urine samples, showing a linear dependence between gB-HCMV concentration and the absorbance signal at 450 nm in a range of concentrations from 90 to 700 pg mL^-1. The calculated detection limits for gB-HCMV were 90 ± 2 pg mL^-1 and the RSD was about 6.7% in urine samples. The immunosensor showed good selectivity against other viruses from Herpesviridae family, namely varicella zoster and Epstein Barr viruses. The recoveries of spiked human urine samples at 0.30-0.50 ng mL^-1 concentration levels of gB-HCMV ranged between 91 to 105%. The proposed mpEIA method was validated following the guidelines of the European Medicines Agency (EMEA-2014), and allows rapid, successful and easy quantification of gB-HCMV in urine samples.

01 May 2012·Journal of Clinical VirologyQ3 · MEDICINE

Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy

Q3 · MEDICINE

Article

Author: Halvor Rollag ; Jutta K. Preiksaitis ; Alan G. Jardine ; Vincent C. Emery ; Anders Asberg ; Atul Humar ; Xiaoli Pang ; Deepali Kumar ; Mark D. Pescovitz ; Oriol Manuel ; Christoph G. Gahlemann ; Anders Hartmann

BACKGROUNDThe impact of different cytomegalovirus (HCMV) glycoprotein B (gB) genotypes on pathogenesis remains controversial.OBJECTIVESTo investigate the effect of gB genotypes either as single infections or as part of multiple infections on the early kinetics of response to ganciclovir therapy.METHODSPatients (n=239) enrolled in a study of intravenous ganciclovir or valganciclovir for the treatment of HCMV disease were analysed by a gB genotype specific PCR to quantify the amount of each gB genotype present at initiation of therapy (baseline, day 0) and at days 3, 7, 14 and 21 post therapy.RESULTS AND CONCLUSIONSIn all gB groups (individual gB genotype infections and mixed genotype infections) there was a biphasic decline in viral load after therapy. The first phase half life (days 0-3) was ≤1 day and was followed over the next 18 days by a slower second phase decline with half lives ranging from 3.4 to 4.4 days. The 1st phase rapid decline in viral load was dependent upon gB genotype whereas the ultimate viral load reduction at day 21 was relatively insensitive to gB genotype. A strong correlation between 1st phase decline and extent of viral load reduction at day 21 was observed (r=0.37; p=0.002). These data imply that early reductions in HCMV load after therapy may be useful in predicting the duration of drug therapy needed to control HCMV replication.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

HCMV gp

Basic Info

Related

Analysis